Rapamycin, but not minocycline, significantly alters ultrasonic vocalization behavior in C57BL/6J pups in a flurothyl seizure model.
Animals
Convulsants
/ pharmacology
Disease Models, Animal
Epilepsy
/ chemically induced
Female
Flurothyl
/ pharmacology
Immunologic Factors
/ pharmacology
MTOR Inhibitors
/ pharmacology
Male
Mice
Mice, Inbred C57BL
Minocycline
/ pharmacology
Seizures
/ chemically induced
Sex Factors
Sirolimus
/ pharmacology
Vocalization, Animal
/ drug effects
Autism
Cell signaling
Cytokines
Early-life seizures
Epilepsy
Ultrasonic vocalizations
Journal
Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872
Informations de publication
Date de publication:
23 07 2021
23 07 2021
Historique:
received:
21
11
2020
revised:
24
02
2021
accepted:
21
04
2021
pubmed:
29
4
2021
medline:
29
1
2022
entrez:
28
4
2021
Statut:
ppublish
Résumé
Epilepsy is one of the most common neurological disorders, with individuals having an increased susceptibility of seizures in the first few years of life, making children at risk of developing a multitude of cognitive and behavioral comorbidities throughout development. The present study examined the role of PI3K/Akt/mTOR pathway activity and neuroinflammatory signaling in the development of autistic-like behavior following seizures in the neonatal period. Male and female C57BL/6J mice were administered 3 flurothyl seizures on postnatal (PD) 10, followed by administration of minocycline, the mTOR inhibitor rapamycin, or a combined treatment of both therapeutics. On PD12, isolation-induced ultrasonic vocalizations (USVs) of mice were examined to determine the impact of seizures and treatment on communicative behaviors, a component of the autistic-like phenotype. Seizures on PD10 increased the quantity of USVs in female mice and reduced the amount of complex call types emitted in males compared to controls. Inhibition of mTOR with rapamycin significantly reduced the quantity and duration of USVs in both sexes. Changes in USVs were associated with increases in mTOR and astrocyte levels in male mice, however, three PD10 seizures did not result in enhanced proinflammatory cytokine expression in either sex. Beyond inhibition of mTOR activity by rapamycin, both therapeutics did not demonstrate beneficial effects. These findings emphasize the importance of differences that may exist across preclinical seizure models, as three flurothyl seizures did not induce as drastic of changes in mTOR activity or inflammation as observed in other rodent models.
Identifiants
pubmed: 33910029
pii: S0166-4328(21)00205-9
doi: 10.1016/j.bbr.2021.113317
pmc: PMC8628310
mid: NIHMS1697837
pii:
doi:
Substances chimiques
Convulsants
0
Immunologic Factors
0
MTOR Inhibitors
0
Flurothyl
9Z467FG2YK
Minocycline
FYY3R43WGO
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
113317Subventions
Organisme : NINDS NIH HHS
ID : R15 NS088776
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Nat Rev Neurol. 2011 Jan;7(1):31-40
pubmed: 21135885
Neurology. 2012 Sep 25;79(13):1384-91
pubmed: 22972641
PLoS One. 2012;7(5):e35885
pubmed: 22567115
Horm Behav. 2012 Aug;62(3):243-53
pubmed: 22387107
Oncotarget. 2018 Jun 1;9(42):26954-26976
pubmed: 29928494
CNS Drugs. 2015 Feb;29(2):91-9
pubmed: 25633849
Epilepsia. 2012 Jul;53(7):1254-63
pubmed: 22612226
Neurosci Lett. 2011 Jun 27;497(3):231-9
pubmed: 21354266
Epilepsy Behav. 2019 Jun;95:26-33
pubmed: 31022661
CNS Neurol Disord Drug Targets. 2016;15(5):533-43
pubmed: 27071790
Exp Neurol. 2015 Jan;263:72-8
pubmed: 25284323
Brain Behav. 2017 Oct 18;7(11):e00857
pubmed: 29201556
Ann Neurol. 2013 Nov;74(5):679-87
pubmed: 23798472
Epilepsy Behav. 2017 Jul;72:58-62
pubmed: 28575768
Epilepsia. 1994;35 Suppl 2:S1-6
pubmed: 8275976
Lancet Neurol. 2002 Oct;1(6):352-8
pubmed: 12849396
Front Pediatr. 2017 Mar 15;5:43
pubmed: 28361047
Exp Neurol. 2014 Jun;256:74-80
pubmed: 24685665
N Am J Med Sci (Boston). 2013;5(3):157-161
pubmed: 24349628
J Neurosci. 2009 May 27;29(21):6964-72
pubmed: 19474323
Epilepsy Behav. 2004 Oct;5(5):649-54
pubmed: 15380115
Prog Brain Res. 2002;135:377-90
pubmed: 12143356
Neurol Sci. 2017 Aug;38(8):1353-1361
pubmed: 28455770
J Child Neurol. 1999 Aug;14(8):485-9
pubmed: 10456756
Epilepsia. 2016 Sep;57(9):1377-85
pubmed: 27378279
Hum Mol Genet. 2011 Dec 15;20(24):4775-85
pubmed: 21908517
Epilepsia. 2008;49 Suppl 2:33-41
pubmed: 18226170
Nat Neurosci. 2001 Jul;4(7):702-10
pubmed: 11426226
PLoS One. 2013;8(3):e57808
pubmed: 23536771
Biochem Pharmacol. 2009 Nov 1;78(9):1242-51
pubmed: 19576187
P T. 2014 Nov;39(11):776-92
pubmed: 25395820
Nat Rev Neurosci. 2004 Jul;5(7):553-64
pubmed: 15208697
Pharmacotherapy. 2006 Apr;26(4):515-21
pubmed: 16553511
Neurobiol Dis. 2004 Jul;16(2):321-34
pubmed: 15193289
Epilepsia. 2015 Jun;56(6):895-905
pubmed: 25847097
Neuropathol Appl Neurobiol. 2018 Feb;44(1):91-111
pubmed: 28977690
Clin Genet. 2018 Feb;93(2):197-205
pubmed: 28617938
Epilepsia. 2002 Sep;43(9):1062-71
pubmed: 12199732
Semin Pediatr Neurol. 2016 May;23(2):120-6
pubmed: 27544468
Ann Neurol. 2018 Feb;83(2):311-327
pubmed: 29331082
Epilepsia. 2011 Nov;52(11):2065-75
pubmed: 21973019
Yonsei Med J. 2008 Feb 29;49(1):1-18
pubmed: 18306464
Epilepsia. 2017 Jul;58 Suppl 3:27-38
pubmed: 28675563
Brain Dev. 2009 Feb;31(2):95-103
pubmed: 19006654
Neurobiol Dis. 2011 Aug;43(2):322-9
pubmed: 21504792
Brain Res. 2012 Feb 23;1439:7-14
pubmed: 22265702
Am J Intellect Dev Disabil. 2010 Sep;115(5):433-43
pubmed: 20687826
Pharmacol Res. 2016 May;107:333-343
pubmed: 27049136
Seizure. 2012 Apr;21(3):227-8
pubmed: 22265576
Neurology. 2016 Dec 6;87(23):2408-2415
pubmed: 27815402
J Neurochem. 2008 Aug;106(4):1929-40
pubmed: 18513371
Epilepsia. 2010 Apr;51(4):676-85
pubmed: 20196795
Epilepsy Res. 2018 Aug;144:62-70
pubmed: 29783181
Epilepsy Behav. 2012 Jul;24(3):314-8
pubmed: 22579030
Nat Rev Neurol. 2019 Aug;15(8):459-472
pubmed: 31263255
Pediatrics. 2011 Dec;128(6):e1532-43
pubmed: 22123895
Brain. 2015 Feb;138(Pt 2):240-2
pubmed: 25627234
P T. 2010 Jul;35(7):392-415
pubmed: 20689626
Mol Psychiatry. 2016 Sep;21(9):1208-14
pubmed: 26666205
J Neurosci. 2015 Feb 25;35(8):3330-45
pubmed: 25716834
Seizure. 2006 Jun;15(4):221-6
pubmed: 16546410
JCI Insight. 2021 May 10;6(9):
pubmed: 33830944
PLoS One. 2008 Aug 27;3(8):e3067
pubmed: 18728777
Mediators Inflamm. 2014;2014:901902
pubmed: 25197169
Epilepsy Behav. 2010 Mar;17(3):412-9
pubmed: 20153981
Neurobiol Dis. 2012 May;46(2):425-30
pubmed: 22366182
J Vis Exp. 2016 Jun 05;(112):
pubmed: 27341321
Neurosci Bull. 2018 Apr;34(2):283-290
pubmed: 28786074
J Neurosci. 2009 Jun 24;29(25):8259-69
pubmed: 19553465
Neurosurg Clin N Am. 1995 Jul;6(3):419-29
pubmed: 7670316
Drug Discov Today. 2007 Feb;12(3-4):112-24
pubmed: 17275731
Epilepsy Behav. 2014 Feb;31:263-6
pubmed: 24230988
Dev Neurobiol. 2017 Jun;77(6):753-766
pubmed: 27706925
Int Rev Neurobiol. 2007;82:247-63
pubmed: 17678965
Expert Rev Neurother. 2013 Jun;13(6):657-69
pubmed: 23739003
Biol Sex Differ. 2011 Jul 11;2:7
pubmed: 21745355
Front Mol Neurosci. 2018 Jan 12;10:452
pubmed: 29375310
Neurosci Lett. 2006 May 8;398(3):195-200
pubmed: 16469440